Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P0DPB6
UPID:
RPAC2_HUMAN
Alternative names:
AC19; DNA-directed RNA polymerase I subunit D; RNA polymerase I 16 kDa subunit; RPC16; hRPA19
Alternative UPACC:
P0DPB6; Q5TBX2; Q96BR3; Q9Y2S0
Background:
DNA-directed RNA polymerases I and III subunit RPAC2, also known as AC19, plays a pivotal role in the transcription of DNA into RNA, utilizing ribonucleoside triphosphates as substrates. It is a core component of RNA polymerases I and III, essential for synthesizing ribosomal RNA precursors and small RNAs, including 5S rRNA and tRNAs.
Therapeutic significance:
RPAC2's involvement in Treacher Collins syndrome 2, a craniofacial development disorder, highlights its critical role in human health. Understanding the role of RPAC2 could open doors to potential therapeutic strategies for this and related conditions.